UPDATE 2-U.S. approves Roche's $4.3 billion purchase of Spark Therapeutics

Swiss drugmaker Roche has won U.S. antitrust approval for its $4.3 billion deal to buy gene therapy specialist Spark Therapeutics clearing the way for Roche's push into treating rare diseases including hemophilia A.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.